Swiss National Bank boosted its holdings in shares of 10x Genomics, Inc. (NASDAQ:TXG – Free Report) by 1.5% in the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 188,400 ...

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com ...

Buy 10x Genomics with a 1-year target of $12.7, projecting 18% growth. Read here for more on TXG stock's biopharma potential ...

Bank of New York Mellon Corp lowered its stake in shares of 10x Genomics, Inc. (NASDAQ:TXG – Free Report) by 13.5% in the ...

Investing.com - 10X Genomics (NASDAQ: TXG) reported second quarter EPS of $-0.53, $0.13 worse than the analyst estimate of $-0.40.

OWKIN and 10x Genomics, Inc. (Nasdaq: TXG), announce they have entered into an agreement to add 10x Genomics spatial omics and ...

Here are three reasons why there are better opportunities than TXG and a stock we'd rather own. Founded in 2012, 10x Genomics (NASDAQ:TXG) develops single-cell and spatial genomics solutions ...

Citi lowered the firm’s price target on 10x Genomics (TXG) to $15 from $20 and keeps a Buy rating on the shares. The firm updated models in the life science tools and diagnostics group post the ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

10x Genomics (NASDAQ:TXG) announced on Monday that its ATAC-Seq patents were found valid and infringed in its patent litigation with Parse Biosciences. On February 25, 2025, a consent agreement ...